Articles On MGC Pharmaceuticals (ASX:MXC)

The MGC Pharmaceuticals Ltd (ASX: MXC) share price has bolted more than 40% higher in morning trade today.    Investors are bidding shares in the pharmaceutical company higher after it released an announcement earlier today. At the time of...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Wall Street snaps three-day gain streak All three US stock market indexes fell last night, and snapped their streak of gains in the previous three days. The Dow Jones fell by 0.54%, S&P500 by 0.58%, and the tech heavy Nasdaq by 0.64%. F...

The phytomedicine group has been the top riser in London on Thursday

European-based biopharma company MGC Pharma (ASX:MXC) has delivered its strongest quarterly sales to date, posting a record $945,000 in revenue for the June quarter. Sales of phytocannabinoid medicines made the majority of revenue, totallin...

Stockhead’s Q-Wrapz video series features one-on-one interviews showcasing the latest quarterly results of emerging ASX companies. In this instalment, former CNBC, Sky News, and Bloomberg news anchor Oriel Morrison interviews Roby Zomer, Co...

Wall Street rises ahead of Fed Reserve decision All three major US benchmarks rose modestly on Monday to reach new records, as the market awaits the result of US Fed’s two-day meeting currently underway. The Dow Jones and S&P 500 were u...

The company's co-founder Roby Zomer said the results meant the group "remains on a strong operational and commercial growth trajectory going into the new financial year"

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

"The acceptance of this patent could be transformational for patients who need treatment and therapeutic relief from neurological diseases"

Summary Kirkland (ASX:KLA) reports record production in second quarter 2021 Finbar (ASX:FRI) rises after forecasting 18% jump in FY net profit Pearl Global (ASX:PG1) climbs on supply deal with Alex Fraser The S&P/ASX200 closed...

MGC Pharmaceuticals (ASX:MXC) has announced that the phase 3 clinical trial evaluating the efficacy and safety of CimetrATM as a treatment for hospitalised patients diagnosed with COVID-19 has commenced following the recruitment of...

CimetrA will be used to treat hospitalised Covide patients

Cannabis stocks have welcomed the change in ownership of Pershing Australia from Bank of New York Mellon (BNYM) to Finclear Pty Ltd which – effective immediately – will allow the trading of cannabis securities on the ASX. In late 2019, BNYM...

The US cannabis sector received a big lift after Amazon announced that job applicants at its offices and warehouses will no longer be drug-tested for marijuana use. Delivery drivers, however, will still be tested. The company also said it w...

The MGC Pharmaceuticals [ASX:MXC] cannabis-derived epilepsy product is set to be fully covered by the HSE in Ireland. The post MGC Pharmaceuticals Share Price Up on CannEpil Update (ASX:MXC) appeared first on Money Morning Australia.

A product formulated by MGC Pharmaceuticals that combats drug-resistant epilepsy will be fully subsidised for patients by Ireland’s health system.

European-based biopharma company MGC Pharmaceuticals (ASX:MXC) has announced that its epilepsy drug, CannEpil, will now be fully covered under Ireland’s Primary Care Reimbursement Service as part of the country’s Medicinal Cannabis Access P...

The European-based company develops and supplies affordable standardised phytocannabinoid-derived medicines to patients globally.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

A glance at some of the day's highlights from the Proactive Investors newswire

MGC Pharmaceuticals says it continues to advance separate clinical trial programs looking to tackle COVID-19, treatment-resistant epilepsy and Alzheimer’s disease. Interim results from all three trials are expected to be released later in t...

All three trials are well funded, following the successful £6.5 million IPO fundraising and listing on the London Stock Exchange in February 2021.

European-based biopharma company MGC Pharmaceuticals (ASX:MXC) has continued to make progress on its major clinical trials planned for 2021. The company has provided an update on the soon-to-commence clinical trials in CimetrA, CannEpil, an...

MGC Pharmaceuticals says a patent application for its CimetrA investigational medical product filed earlier this month has been accepted by the Slovenian Intellectual Property Office, giving it an avenue to seek patent protection in other E...

CimetrATM has been designed for multiple therapeutic applications including acute and chronic inflammation, COVID-19 and variants of influenza, autoimmune diseases, adverse events resulting from the various forms of cancer therapy.

LBT Innovations (ASX:LBT) shares rose this morning after it sold its first two pathology sample analysers in the UK. LBT’s APAS Independence (Automated Plate Assessment System) sorts medical samples and uses AI and machine learning to deter...

European-based biopharma company MGC Pharmaceuticals (ASX:MXC) has just announced major progress in its anti-inflammation drug, CimetrA, having recently submitted the patent application to the European IP Office. The patent application was...

The bio-pharma firm said it expects the patent to be issued from the Slovenian Intellectual Property Office within the next 12 months

Summary The benchmark index was up today, with most of the indices trading in the green zone. archTIS has secured a contract with an Australian national security agency to procure extra NC Protect software licences. Xref Limited repor...

There was shock and confusion in the North American cannabis industry last week, after news broke that the international banking firm, Credit Suisse Group, had announced to customers that it will no longer be executing stock transactions fo...

MGC Pharmaceuticals appears to have delivered a breakthrough in its ArtemiC Rescue supplement’s ability to act as an anti-inflammatory agent to treat COVID-19 and post COVID-19 symptoms. Further trials are now on the cards following the lat...

European-based biopharma company MGC Pharmaceuticals (ASX:MXC) has just announced exciting further results from the Phase II clinical trials and pre-clinical studies of ArtemiCTM, for the treatment of COVID-19 patients. These studies are ev...

The mechanism of action of ArtemiC is focused on the anti-inflammatory effect and prevention of cytokine storm

The ASX 200 has rebounded from yesterday’s loss though the technology sector has weighed on the market for two consecutive weeks. The index closed 0.20 per cent higher, and is also up by 0.70 per cent for the week. IT slumped by another 2.5...

The ASX finished the day in the red and the tech sector dropped more than any other sector. The ASX 200 closed at 7,062 which was 0.48 per cent down from yesterday and tech stocks shed over 3.5 per cent. The only other sector to fall over 1...

Its securities will remain halted until the start of normal trading on Monday, May 10, 2021, or until an announcement is released to the market.

Summary The increase in the level of digitisation has led to a rise in the number of scams in Australia, resulting in substantial financial losses. archTIS signed an agreement with the Australian Department of Defence for software supp...

MGC Pharmaceuticals has secured a $1 million order for its COVID-19 supplement ArtemiC Rescue from nutraceuticals producer and distributor Swiss PharmaCan AG. The purchase marks the second major wholesale order since entering an exclusive a...

Phase 2 trials have shown ArtemiC’s ability to reduce symptoms and pain associated with COVID-19 and achieve faster clinical improvements.

European-based biopharma company MGC Pharmaceuticals (ASX:MXC) has just received $1 million worth of orders for its ArtemiCTM Rescue food supplement. The order was received from its distribution partner Swiss PharmaCan (SPC), and is the sec...

Summary 5G Networks reported robust growth across all three core products in Q3 FY21 and witnessed a growing demand for the 5GN Voice Bridge One Microsoft Teams product. JB Hi-Fi witnessed double-digit sales growth in two of its three...

Summary Oventus Medical witnessed growth in booked revenue and acceleration in telehealth bookings in Q3 FY21. ECS Botanics Holdings’ March 2021 quarter was action-packed with a major acquisition and multiple supply agreements. Despit...

Summary MGC Pharmaceuticals rallied by 8.7% to A$0.062 as its Canada-based North American distribution partner is seeking product licences. Hexagon Energy is in news as it has agreed to select Air Products and Chemicals Inc as its key...

The ASX-listed bio-pharma company’s Canadian distribution partner — which it collaborated with to create an oral spray statistically shown to improve the recovery of patients with COVID-19 — has now applied for additional product licences i...

Glow LifeTech has exclusive rights to market, sell and distribute ArtemiC™ in Canada, USA, Mexico and all Caribbean countries as a food supplement (nutraceutical, dietary supplement, natural health product).

Summary Respiri Limited has partnered with Australia’s largest pharmacy network, TerryWhite Chemmart, for the sale and marketing of wheezo™. This agreement brings the total number of pharmacies contracted to stock and sell wheezo to 1,...